Bevacizumab FOLFOX Protocol for Metastatic Colorectal Cancer
For adult patients with metastatic colorectal cancer, administer bevacizumab 5 mg/kg intravenously every 2 weeks combined with FOLFOX (oxaliplatin 85 mg/m² IV over 2 hours on Day 1, leucovorin 200 mg/m² IV over 2 hours on Days 1-2, fluorouracil 400 mg/m² IV bolus followed by 600 mg/m² as 22-hour continuous infusion on Days 1-2), repeated every 14 days until disease progression or unacceptable toxicity. 1, 2
Dosing Schedule
Day 1:
- Bevacizumab: 5 mg/kg IV infusion over 90 minutes (first infusion), subsequent infusions can be shortened to 60 minutes if tolerated 2
- Oxaliplatin: 85 mg/m² IV over 120 minutes (can be extended to 6 hours if infusion reactions occur) 1
- Leucovorin: 200 mg/m² IV over 120 minutes (concurrent with oxaliplatin in separate bag) 1
- Fluorouracil: 400 mg/m² IV bolus over 2-4 minutes, then 600 mg/m² as 22-hour continuous infusion 1
Day 2:
- Leucovorin: 200 mg/m² IV over 120 minutes 1
- Fluorouracil: 400 mg/m² IV bolus over 2-4 minutes, then 600 mg/m² as 22-hour continuous infusion 1
Repeat cycle every 14 days 1, 2
Clinical Context and Evidence
The 2023 ASCO guideline addresses whether doublet chemotherapy (FOLFOX) is appropriate for patients receiving bevacizumab, confirming this as standard practice for previously untreated metastatic colorectal cancer 3. The NCCN 2024 guidelines support bevacizumab at 5 mg/kg every 2 weeks as the preferred angiogenic agent based on toxicity and cost considerations 4.
First-line setting: The pivotal AVF2107g trial demonstrated that bevacizumab 5 mg/kg every 2 weeks with chemotherapy improved median overall survival to 20.3 months versus 15.6 months with chemotherapy alone (HR 0.66, p<0.001) 2. This 5 mg/kg dose is FDA-approved and appropriate for first-line treatment 2.
Second-line setting: If bevacizumab was not used first-line, the E3200 study established that bevacizumab 10 mg/kg every 2 weeks with FOLFOX4 improved median survival to 12.9 months versus 10.8 months with FOLFOX4 alone (HR 0.75, p=0.0011) 2, 5. Note the higher dose (10 mg/kg) for second-line therapy 2.
Critical Dose Modifications
For Peripheral Neuropathy (oxaliplatin-related):
- Persistent Grade 2: Consider reducing oxaliplatin to 75 mg/m² 1
- Persistent Grade 3: Consider discontinuing oxaliplatin 1
- Grade 4: Discontinue oxaliplatin permanently 1
For Myelosuppression:
- Grade 4 neutropenia or febrile neutropenia: Delay next cycle until neutrophils ≥1.5 × 10⁹/L and platelets ≥75 × 10⁹/L, then reduce oxaliplatin to 75 mg/m² 1
For Gastrointestinal Toxicity:
- Grade 3-4: After recovery, reduce oxaliplatin to 75 mg/m² and fluorouracil to 300 mg/m² bolus and 500 mg/m² continuous infusion 1
Bevacizumab-Specific Safety Monitoring
Permanently discontinue bevacizumab for: 1
- Hypersensitivity reactions or anaphylaxis
- Gastrointestinal perforation (2% incidence) 6
- Wound dehiscence requiring intervention
- Severe hemorrhage
- Arterial thromboembolic events
- Hypertensive crisis
- Nephrotic syndrome
- Posterior reversible encephalopathy syndrome (PRES)
Common bevacizumab adverse events requiring management:
- Hypertension (5.3% Grade 3-5): Monitor blood pressure and treat proactively 6
- Proteinuria (1% serious): Monitor urine protein regularly 6
- Bleeding (3% serious): Avoid in patients with recent hemoptysis or CNS metastases 6
Important Clinical Pitfalls
Surgical timing: Discontinue bevacizumab at least 28 days before elective surgery due to wound-healing complications (1% incidence). Do not resume until surgical wound is fully healed 2, 6.
Continuation beyond progression: The NCCN guidelines support continuing bevacizumab through second-line therapy if used first-line, based on modest survival benefit (HR 0.76) 4. However, bevacizumab monotherapy is not recommended as it showed inferior efficacy compared to chemotherapy alone 2.
Infusion reactions: The first bevacizumab infusion should be given over 90 minutes; if tolerated, subsequent infusions may be shortened to 60 then 30 minutes 2. Oxaliplatin infusion time can be extended from 2 to 6 hours to mitigate acute toxicities 1.
Duration of Therapy
Continue treatment until disease progression or unacceptable toxicity 1, 2. For adjuvant treatment (Stage III colon cancer), limit to 12 cycles, though this protocol specifically addresses metastatic disease where duration is not capped 1.
The real-world BEAT study confirmed this regimen's safety profile is consistent across diverse patient populations, with 60-day mortality of 3% and median progression-free survival of 10.8 months 6.